ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California. Show more
Location: 11682 El Camino Real, San Diego, CA, 92130, United States | Website: https://ars-pharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.737B
52 Wk Range
$8.91 - $18.90
Previous Close
$17.98
Open
$17.98
Volume
1,112,998
Day Range
$17.46 - $18.04
Enterprise Value
1.508B
Cash
275.7M
Avg Qtr Burn
-5.121M
Insider Ownership
16.94%
Institutional Own.
80.28%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I) | Approved Quarterly sales | |
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I) | Approved Quarterly sales | |
neffy® (epinephrine nasal spray) Details Acute flares in patients with chronic spontaneous urticaria | Phase 2b Initiation | |
SBT6050 (TLR8 Agonist) Details Cancer, Breast cancer | Failed Discontinued |